{
  "id": "c72d1a5259d1",
  "type": "finding",
  "topic": "Zepbound Q4 2025 revenue estimation",
  "summary": "Central estimate ~$4,200-4,400M based on multiple approaches: QoQ growth, YoY growth, seasonal patterns, and full-year guidance constraints",
  "content": "Quarterly Zepbound revenue (M USD): Q1'24:517, Q2'24:1243, Q3'24:1258, Q4'24:1907, Q1'25:2312, Q2'25:3381, Q3'25:3588. \n\nKey patterns: Q3→Q4 seasonal uplift (+51.6% in 2024), YoY growth decelerating (347%→172%→185%). Full-year 2025 Lilly guidance: $63-63.5B (raised after Q3 beat). Earnings date: Feb 4, 2026. No pre-announcement warning found. Zepbound price cuts announced Dec 2025. Multiple estimation approaches converge on ~$4,200-4,400M central estimate.",
  "sources": [
    "https://investor.lilly.com/news-releases/news-release-details/lilly-reports-third-quarter-2025-financial-results-highlights-rd",
    "https://www.statista.com/statistics/1636037/eli-lilly-zepbound-revenue/"
  ],
  "confidence": 0.7,
  "question_id": 0,
  "report_path": "",
  "created_at": "2026-02-06T22:52:06.733946Z"
}